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Background: The clinical outcomes of ST-segment elevation myocardial infarction (STEMI) are poor in patients with
renal insufficiency. This study investigated changes in the likelihood that patients received optimal medical care
throughout the entire process of myocardial infarction management, on the basis of their glomerular filtration
rate (GFR).
Methods: This study analyzed 7,679 patients (age, 63 ± 13 years; men 73.6%) who had STEMI and were enrolled
in the Korea Acute Myocardial Infarction Registry (KAMIR) from November 2005 to August 2008. The study
subjects were divided into 5 groups corresponding to strata used to define chronic kidney disease stages.
Results: Patients with lower GFR were less likely to present with typical chest pain. The average symptom-to-door
time, door-to-balloon time, and symptom-to-balloon time were longer with lower GFR than higher GFR. Primary
reperfusion therapy was performed less frequently and the results of reperfusion therapy were poorer in patients
with renal insufficiency; these patients were less likely to receive adjunctive medical treatment, such as treatment
with aspirin, clopidogrel, β-blocker, angiotensin-converting enzyme (ACE) inhibitor/angiotensin-receptor blocker
(ARB), or statin, during hospitalization and at discharge. Patients who received less intense medical therapy had
worse clinical outcomes than those who received more intense medical therapy.
Conclusions: Patients with STEMI and renal insufficiency had less chance of receiving optimal medical care
throughout the entire process of MI management, which may contribute to worse outcomes in these patients.
Keywords: Myocardial infarction, Optimal medical care, Renal functionBackground
Acute coronary syndrome (ACS) is the leading cause of
death in patients with chronic kidney disease (CKD)
[1,2]. The severity of renal insufficiency, including mild
to moderate renal insufficiency is directly associated with
increased cardiovascular morbidity and mortality [3,4].
Several factors may be related to poorer outcomes of
ACS in patients with renal insufficiency. Hypertension,
dyslipidemia, and diabetes mellitus (DM) are common* Correspondence: skimw@chonnam.ac.kr
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reproduction in any medium, provided the oramong patients with renal insufficiency and are often in-
adequately treated in this population [5]. In addition, the
accumulation of uremic toxins can stimulate oxidative
stress and inflammation, and hence, contribute to endo-
thelial dysfunction and atherosclerosis progression [6].
Primary management in patients with ST-segment ele-
vation myocardial infarction (STEMI) includes timely
restoration of flow in the stenosed artery—either by
fibrinolysis or by percutaneous coronary intervention
(PCI)—to limit the extent of infarction in the myocar-
dium. In addition, medications (anti-platelet agent, β-
blocker, angiotensin-converting enzyme [ACE] inhibitor
or angiotensin-receptor blocker [ARB] and statin) formd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment. These management strategies have contributed
to improved survival in patients with STEMI. However,
only a few studies have evaluated how renal function
affects the likelihood of receiving optimal medical care
throughout the entire treatment period in patients
with STEMI.
The purpose of this study was to investigate whether
renal insufficiency is associated with a decreased likeli-
hood of receiving optimal medical care in patients with
STEMI. The entire medical treatment process for
patients with STEMI was comprehensively analyzed, and
the relationship between optimal management and clin-
ical outcomes in patients with renal insufficiency was
investigated.
Methods
Korea acute myocardial infarction registry
The study population was derived from the Korea Acute
Myocardial Infarction Registry (KAMIR). The KAMIR
is a prospective, open, observational, multicenter online
registry investigating the risk factors for mortality in
patients with acute myocardial infarction (AMI) in
Korea since November 2005. Through the support of
the Korean Circulation Society, 52 community and uni-
versity hospitals that had facilities for primary PCI and
sufficient experience with the procedure participated in
KAMIR with the aim of establishing clinical practice
guidelines for AMI. The name of each participation
centers listed in the Appendix 1 and 2. Data were col-
lected at each site by a trained study coordinator by
using a standardized protocol. The study protocol was
approved by the ethics committee at each participating
institution. All patients gave written informed consent
before enrollment.
Study population
This study retrospectively analyzed a cohort of 7,679
consecutive patients who were admitted to the hospital
between November 1, 2005, and July 31, 2008, and had
a discharge diagnosis of STEMI, confirmed by both
cardiac enzyme and electrocardiogram analyses. The
diagnosis of STEMI was based on a suggestive history,
with ST elevation > 2 mm in ≥2 precordial leads, ST
elevation > 1 mm in ≥2 limb leads, or new left branch
bundle block on the 12-lead electrocardiogram with
a concomitant increase of cardiac markers ≥2 times
the upper limit of normal. Patients were excluded if an
estimated glomerular filtration rate (GFR) could not
be calculated.
Renal function was based on GFR estimation. The
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation was used to estimate GFR in millili-
ters per minute per 1.73 m2 [7]. The study populationwas divided into 5 groups according to the estimated
GFR: group I, GFR ≥ 90 mL/min/1.73 m2 (2099 patients;
age, 54 ± 11 years; men, 83.1%); group II, 60 ≤ GFR <
90 mL/min/1.73 m2 (3647 patients; age, 63 ± 12 years;
men, 75.8%); group III, 30 ≤GFR< 60 mL/min/1.73 m2
(1600 patients; age, 71 ± 11 years; men, 60.6%); group IV,
15 ≤GFR< 30 mL/min/1.73 m2 (210 patients; age,
73 ± 11 years; men, 45.2%); and group V, GFR < 15 mL/
min/1.73 m2 (123 patients; age, 66 ± 13 years; men,
64.2%).
Data collection
The baseline variables included age; gender; body mass
index (BMI); and several coronary risk factors such as
hypertension (defined as history of hypertension and
admission blood pressure > 140 mm Hg systolic or >
90 mm Hg diastolic), DM (defined as history of DM or
random blood glucose level > 200 mg/dL), hyperlipid-
emia (defined as history of hyperlipidemia, total choles-
terol level of > 240 mg/dL, or low density lipoprotein
[LDL] level > 101 mg/dL), history of smoking, history
of ischemic heart disease (IHD), clinical symptoms at
admission (chest pain or dyspnea), and Killip class. One
of the following 3 modalities was selected as primary
reperfusion therapy for patients with STEMI: intraven-
ous thrombolytic therapy, primary PCI, or facilitated
PCI. The use of certain medications (aspirin, clopidogrel,
ACE inhibitor, ARB, β-blocker or statin) during the in-
hospital period and at discharge was also recorded.
MACE was defined as a composite outcome of cardiac
death, repeated PCI, or MI.
Statistical analysis
Continuous variables with normal distributions are
expressed as mean± SD, and the 5 groups were com-
pared using one-way ANOVA. Continuous data with a
skewed distribution are presented as median (with 25th
and 75th percentiles) and were compared using the
Kruskal-Wallis test. Categorical variables were compared
using the chi-square test or the Fisher’s exact test if the
expected value of the variable was <5 in at least 1 group.
Survival analysis after MI was estimated using the
Kaplan-Meier method with log-rank tests to compare
survival among groups. All statistical tests were 2-tailed,
and p<0.05 was considered significant. Analyses were per-
formed using the Statistical Package for Social Sciences
software, version 18.0 (IBM, Armonk, NY USA).
Results
Baseline characteristics
A total of 7,679 patients (age, 63 ± 13 years; men, 73.6%)
were included in the present study. The baseline charac-
teristics and biochemical parameters of patients are
shown in Table 1. A lower GFR was associated with
Table 1 Baseline characteristics
Group I (n = 2099) Group II (n = 3647) Group III (n = 1600) Group IV (n = 210) Group V (n = 123) P value
Age, years 54 ± 11 63 ± 12 71 ± 11 73 ± 11 66 ± 13 <0.001
Male 1745(83.1) 2763(75.8) 970(60.6) 95(45.2) 79(64.2) <0.001
BMI, kg/m2 24 ± 3 24± 3 24± 3 23± 3 24± 3 0.284
Past History
Hypertension 739(35.3) 1571(43.2) 953(59.8) 156(74.6) 75(61.5) <0.001
DM 445(21.3) 789(21.7) 505(31.7) 99(47.6) 60(48.8) <0.001
Previous IHD 190(9.1) 420(11.6) 239(15.1) 39(18.8) 29(23.6) <0.001
Hyperlipidemia 184(8.8) 273(7.5) 121(7.6) 17(8.1) 8(6.6) 0.171
Smoking 1276(61.1) 1779(49.1) 493(31.2) 53(25.9) 39(32.2) <0.001
At admission
SBP (mmHg) 130± 26 127 ± 28 117 ± 33 111± 36 123 ± 35 <0.001
DBP (mmHg) 81 ± 16 78 ± 17 72 ± 19 70 ± 23 75 ± 21 <0.001
Killip class 1.3 ± 0.7 1.4 ± 0.8 1.8 ± 1.1 2.1 ± 1.2 2.0 ± 1.2 <0.001
LVEF (%) 52 ± 11 51 ± 12 48 ± 13 47 ± 14 47 ± 12 <0.001
Biochemical parameters
Creatinine (mg/dL) 0.8 ± 0.1 1.0 ± 0.2 1.4 ± 0.3 2.3 ± 0.5 9.5 ± 8.9 <0.001
Troponin-I (ng/mL) 40(9,79) 30(7,68) 28(5,73) 31(10,56) 28(6,51) 0.007
CK-MB (U/L) 133(38,277) 132(40,283) 112(26,243) 84(27,195) 69(20,176) <0.001
TC (mg/dL) 188± 44 183 ± 43 175 ± 45 165± 42 174 ± 60 0.004
LDL (mg/dL) 122± 42 116 ± 42 112 ± 41 100± 39 106 ± 52 0.026
TG (mg/dL) 109(72,163) 98(66,143) 95(66,140) 105(74,152) 91(66,150) <0.001
Glucose (mg/dL) 161± 66 168 ± 70 201± 100 234± 134 201± 106 <0.001
hs-CRP (mg/dL) 0.6(0.2,3.4) 0.8(0.2,4.2) 1.3(0.3,7.0) 4.6(0.8,15.0) 2.1(0.6,9.8) <0.001
NT-proBNP (pg/mL) 223 (57,871) 346 (75,1414) 1144 (230,3973) 5423 (1296,21374) 21191 (4957,35000) <0.001
Continuous data are expressed as the mean ± SD or the median and interquartile range (25th and 75th percentiles). Categorical data were expressed as
percentages. Abbreviations: BMI, body mass index; DM, diabetes mellitus; IHD, ischemic heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure;
LVEF, left ventricular ejection fraction; CK-MB, creatine kinase-MB; TC, total cholesterol; LDL, low density lipoprotein; hs-CRP, high-sensitivity C-reactive protein;
NT-proBNP, N-terminal pro B-type natriuretic peptide.
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tension, DM, history of IHD, and lower likelihood of
being a current smoker. At the time of hospital arrival, a
lower GFR was associated with lower blood pressure,
lower left ventricular ejection fraction (LVEF), and
higher Killip class. In patients with lower GFR, the totalTable 2 Presence of typical chest pain and time of restoration
Group I Group II
Presence of chest pain 1916(91.8) 3215(88.7)
Symptom to door time, hr 3.5(1.8,7.7) 3.3(1.6,8.2)
Primary PCI †
Door to ballon time, hr 1.5(1.1,2.9) 1.5(1.0,2.3)
Symptom to ballon time, hr 5.6(3.4,13.0) 4.8(3.1,10.1)
Thrombolysis {
Door to needle time, hr 0.9(0.6,1.5) 0.9(0.6,1.4)
Symptom to needle time, hr 3.5(2.2,5.0) 3.4(2.4,5.1)
Continuous data are expressed as the median and interquartile range (25th and 75
PCI, percutaneous intervenyion;
† The subject who received primary reperfusion therapy as primary percutaneous in
{ The subject who received primary reperfusion therapy as thrombolytic therapy, (ncholesterol, LDL, triglyceride, troponin-I, and creatine
kinase-MB (CK-MB) levels were lower, whereas the
glucose, high sensitivity C-reactive protein (hs-CRP), N-
terminal prohormone of brain natriuretic peptide (NT-
pro BNP) levels were higher than in patients with
higher GFR.of infarcted-artery
Group III Group IV Group V P value
1305(82.2) 154(74.4) 80(66.1) <0.001
3.8(1.8,9.7) 5.4(2.1,15.5) 4.8(1.8,16.1) <0.001
1.5(1.1,2.4) 1.7(1.2,2.6) 1.9(1.3,4.6) <0.001
5.4(3.3,10.8) 8.3(4.2,18.4) 7.2(3.3,26.0) <0.001
0.9(0.6,1.4) 1.2(0.4,5.8) 0.8(0.4,-) 0.876
3.4(2.4,5.1) 5.0(4.1,9.0) 11.0(0.8,-) 0.316
th percentiles). Categorical data were expressed as percentages. Abbreviations:
tervention (PCI), (n = 5,607).
= 618).
Figure 1 Initial reperfusion strategy in STEMI patients.
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Patients with lower GFRs were less likely to present with
typical chest pain. The time to restoration of flow in the
stenosed artery was analyzed in the following ways:
symptom-to-door time in all patients; door-to-balloon
time and symptom-to-balloon time in patients who
underwent primary PCI as initial reperfusion therapy;
door-to-needle time and symptom-to-needle time in
patients who received thrombolysis as initial reperfusion
therapy (Table 2). Patients with lower GFRs tended to
have longer symptom-to-door times. In patients with
lower GFRs, door-to-balloon time and symptom-to-
balloon time also tended to be longer when primary PCI
was the initial reperfusion therapy. In contrast, door-to-
needle time and symptom-to-needle time were not sig-
nificantly different in patients with lower GFRs.
Initial treatment strategy and results of reperfusion
therapy
In the initial selection of treatment strategy in patients
with STEMI, conservative treatment was more commonlyTable 3 Results of reperfusion therapy
Group I Group II Gro
Result of PCI †
Patients, n 1974(95.9) 3406(94.9) 1437
Success 1832(92.8) 3139(92.2) 1286
Suboptimal 40(2.0) 83(2.3) 44
Failed 102(5.2) 184(5.4) 107
Result of thrombolysis {
Patients, n 290(14.0) 367(10.2) 119
Success 222(76.6) 262(71.4) 83(
Failed 68(23.4) 105(28.6) 36(
Data are presented as number of patients (percentage). Abbreviations: PCI, percuta
† The subject who received PCI during in-hospital period regardless of its subtype (
{ The subject who received thrombolysis therapy during in-hospital period (thrombperformed but thrombolysis was less frequently per-
formed in patients with lower GFRs (Figure 1). During
the in-hospital period, PCI, regardless of its subtype
(primary PCI, facilitated PCI, or rescue PCI), was less
frequently performed in patients with lower GFR, and
its success rate markedly decreased with decrease in
GFR (Table 3). In addition, thrombolysis was also per-
formed less frequently in patients with lower GFR, and
the success rate of thrombolysis decreased with decrease
in GFR.
Angiographic finding
Angiographic findings are shown in Table 4. Multivessel
coronary artery disease and disease of the left main cor-
onary artery were more common in groups with lower
GFR. Initial TIMI flow 0 (no flow) and presence of a
complex lesion (type C) were more frequently observed
and a final TIMI flow 3 (complete perfusion) was less
frequently observed with lower GFR. Patients with lower
GFR were treated with a greater number of stents than
patients with higher GFRs.up III Group IV Group V P value
(91.3) 181(87.4) 104(86.0) <0.001
(89.5) 151(83.4) 86(82.7) <0.001
(3.1) 6(3.3) 5(4.8)
(7.4) 24(13.3) 13(12.5)
(7.5) 11(5.3) 6(5.0) <0.001
69.7) 3(27.3) 3(50.0) 0.003
30.3) 8(72.7) 3(50.0)
neous intervention.
primary PCI, facilitated PCI, rescue PCI), (n = 7,102).
olysis only, facilitated PCI), (n = 793).
Table 4 Angiographic data
Group I Group II Group III Group IV Group V P value
Number of vessel
One vessel 1044(53.2) 1599(47.2) 508(35.6) 42(23.3) 31(30.1) <0.001
Two vessel 527(26.9) 1035(30.6) 466(32.7) 66(36.7) 30(29.1) <0.001
Three vessel 354(18.1) 682(20.1) 405(28.4) 62(34.4) 35(34.0) <0.001
LM 36(1.8) 70(2.1) 47(3.3) 10(5.6) 7(6.8) <0.001
ACC/AHA lesion C 903(48.9) 1625(51.4) 714(53.8) 108(65.5) 57(59.4) <0.001
Initial TIMI flow grade 0 938(49.7) 1763(54.1) 772(56.1) 102(59.3) 41(41.8) 0.007
Final TIMI flow grade 3 1728(94.3) 2913(91.6) 1181(88.1) 139(84.2) 76(81.7) <0.001
Stent number 1.40 ± 0.74 1.44 ± 0.77 1.48 ± 0.81 1.49 ± 0.75 1.52 ± 0.88 0.002
Stent diameter, mm 3.21 ± 0.42 3.21 ± 0.44 3.15 ± 0.45 3.10 ± 0.43 3.22 ± 0.42 0.655
Stent length, mm 25.0 ± 6.3 25.1 ± 6.2 25.3 ± 6.4 26.4 ± 6.8 24.7 ± 6.5 0.802
Data are presented as mean ± SD or number of patients (percentage). Abbreviations: TIMI, Thrombolysis In Myocardial Infarction.
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Table 5 lists specific medical treatments received prior
to PCI, both during the in-hospital period and at dis-
charge, according to GFR. The use of an anti-platelet
agent prior to PCI was not significantly different among
the groups. During in-hospital periods, standard medica-
tions known to improve survival after MI, such as anti-
platelet agent, β-blocker, ACE inhibitor or ARB, and sta-
tin were less frequently used in patients with lower GFR.
The underuse of these drugs was not corrected until
hospital discharge of the patients who survived STEMI.
We evaluated the correlation between clinical outcomes
and intensity of evidence-based medication in patientsTable 5 Intense of medical therapy
Group I Group II Gro
Pre-PCI medication
Patients, n 1974 3406 1
Aspirin 796(40.3) 1366(40.1) 565
Clopidogrel 748(37.9) 1299(38.1) 528
In-hospital medication
Patients, n 2099 3647 1
Aspirin 2069(98.6) 3594(98.5) 154
Clopidogrel 2048(97.6) 3540(97.1) 152
β-blocker 1619(77.1) 2581(70.8) 100
ACEi or ARB 1754(83.6) 2906(79.7) 116
Statin 1630(77.7) 2716(74.5) 103
Discharge medication
Patients, n 2067 3519 1
Aspirin 1980(95.8) 3390(96.3) 130
Clopidogrel 1927(93.2) 3276(93.1) 126
β-blocker 1528(73.9) 2412(68.5) 921
ACEi or ARB 1691(81.8) 2789(79.3) 107
Statin 1577(76.3) 2610(74.2) 941
Data are presented as number of patients (percentage). Abbreviations: PCI, percuta
ARB, angiotensin receptor blocker.with GFR< 60 mL/min/1.73 m2. In the hospital period,
the patients who received less intense medical therapies
had worse clinical outcomes than those who received
more intense medical therapies. Similar observations
were made for discharge medications among patients
who survived STEMI (Figure 2).
Outcomes according to GFR
The clinical outcomes in patients with STEMI are listed
in Table 6. At 1 month, MACE and all-cause death were
higher in patients with lower GFRs. At 12 months,
MACE and all-cause death also increased as decreas-
ing GFRs.up III Group IV Group V P value
437 181 104 96
(39.3) 76(42.0) 53(51.0) 0.476
(36.7) 71(39.2) 49(47.1) 0.622
600 210 123
4(96.5) 197(93.8) 118(95.9) <0.001
2(95.1) 192(91.4) 114(92.7) <0.001
3(62.7) 115(54.8) 71(57.7) <0.001
5(72.8) 132(62.9) 73(59.3) <0.001
4(64.6) 125(59.5) 79(64.2) <0.001
373 151 91
3(94.9) 139(92.1) 86(94.5) 0.054
6(92.2) 131(86.8) 81(89.0) 0.012
(67.1) 99(65.6) 58(63.7) <0.001
0(77.9) 105(69.5) 66(72.5) <0.001
(68.5) 101(66.9) 61(67.0) <0.001
neous coronary intervention; ACEi, angiotensin converting enzyme inhibitor;
Figure 2 Kaplan-Meier estimates of cumulative survival according to intense of medical therapies. (A) 1 month cumulative survival
according to intense of in-hospital medications (B) 1 year cumulative survival according to intense of discharge medications; medications†, sum
of prescription of aspirin, clopidogrel, beta-blocker, angiotensin converting enzyme inhibitor or angiotensin receptor blocker and statin.
Choi et al. BMC Nephrology 2012, 13:110 Page 6 of 9
http://www.biomedcentral.com/1471-2369/13/110Discussions
The principal finding of this study is that patients who
have renal insufficiency and develop STEMI are less
likely to receive optimal therapy. Patients with renal
insufficiency more often presented with atypical symp-
toms and had longer delays in both hospital arrival and
reperfusion. In addition, primary reperfusion therapy
was performed less frequently in patients with renal
insufficiency and the results of reperfusion therapy were
worse with lower GFR. Patients with renal insufficiency
were less likely to receive life-saving medical medicationsTable 6 Outcomes according to the GFR
Group I Group II Gro
1 month outcomes
MACE 64(3.5) 217(6.9) 284
All-cause death 41(2.0) 160(4.4) 263
12 month outcomes
MACE 183(8.7) 382(10.5) 351
All-cause death 60(4.4) 195(8.2) 304
Data are presented as number of patients (percentage). Abbreviations: MACE, majosuch as anti-platelet agent, β-blocker, ACE inhibitor/
ARB, or statin during hospitalization and at discharge.
A recent study reported that the probability of patients
with MI presenting without chest pain increased propor-
tionally with a decrease in GFR [8]. Canto et al. also
showed that patients with MI, but without chest pain,
are at increased risk for delays in seeking medical atten-
tion, less aggressive treatment, and have higher asso-
ciated in-hospital mortality [9]. Taken together, these
findings suggest that patient with renal insufficiency may
have less chance of receiving timely medical care, whichup III Group IV Group V P value
(20.6) 74(41.8) 37(35.2) <0.001
(16.4) 71(33.8) 35(28.5) <0.001
(21.9) 78(37.1) 46(37.4) <0.001
(27.1) 79(54.9) 41(48.8) <0.001
r adverse cardiovascular event.
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in the time to restoration of flow in the stenosed artery
was also observed with lower GFR in patients who had
STEMI and underwent primary PCI. Rapid reperfusion
is an important goal in the treatment of STEMI patients
[10,11]. However, patients with renal insufficiency
arrived at the hospital relatively late with respect to
symptom onset, and clinicians may be reluctant to make
an immediate decision in patients with renal insuffi-
ciency because of the presence of more comorbidities
and increased complexity of medical care.
During the hospital period, reperfusion therapy, re-
gardless of its subtype, was used less frequently in
patients with lower GFR, which was consistent with pre-
vious studies [12,13]. Older age, more comorbidities,
compromised hemodynamic status, and fear of compli-
cations such as bleeding and contrast-induced nephropa-
thy may all affect a clinician’s decision. In addition, the
results of reperfusion therapy were disappointing in
patients with renal insufficiency. A higher incidence
of multivessel disease, more complex lesions, and poor
coronary blood flow before and after PCI may contribute
to the poor results of reperfusion therapy. Although
the exact pathophysiologic mechanisms by which renal
insufficiency adversely affect the results of reperfusion
therapy have not been clearly elucidated, oxidative stress,
endothelial cell dysfunction, and more advanced athero-
sclerosis may play a role in this regard [14-17].
Although, renal insufficiency is an important risk fac-
tor for increased mortality, patients with lower GFR
were less likely to receive adjunctive medical therapies
recommended by current guidelines. This finding is con-
sistent with previous reports [18,19]. The underuse of
life-saving medications may result from fear of adverse
effects. Clinicians are often reluctant to use an anti-
platelet agent for patients with renal insufficiency
because of the risk of bleeding. Similarly, hyperkalemia
or renal function deterioration often pushes clinicians to
withhold ACE inhibitor/ARB therapy. However, evidence
indicates that these medications are associated with great
survival benefits in patients with renal insufficiency, even
in the case of severe renal insufficiency [20-22]. In clin-
ical practice, clinicians who assess the risks and benefits
of medication should consider the fact that the long-
term cardioprotective and survival benefits outweigh the
risk associated with short-term adverse effects.
The mortality rate associated with MI has fallen con-
siderably in recent decades [23,24]. Improvements in
emergency system response times and diagnostic tech-
niques may explain some of the improvements in MI
mortality. Advances in medical treatment and cardiac
interventions have also played a role in this improve-
ment. Despite these advances, data from this study indi-
cate that patients with renal insufficiency were less likelyto receive optimal medical care throughout the entire
process of MI management and that these differences
may contribute to worse outcomes in patients from the
KAMIR data population who had lower GFR and devel-
oped MI [4,25].
The present study has some limitations. First, KAMIR
is a multicenter retrospective registry study and not a
randomized controlled study. Therefore, unmeasured
factors in the KAMIR database could influence these
findings. Second, assessment of kidney function in this
study was based on a single serum creatinine value
obtained at the time of presentation to the hospital. This
value may have been affected by hemodynamic or meta-
bolic status. Third, although, estimating GFR based on
serum creatinine are preferable method for accessing
renal function in the clinical practice, it is influenced by
various factors such as age, gender, ethnics, muscle mass
and nutritional status. This could confound the relation-
ship between GFR and likelihood of receiving optimal
medical care in patients with STEMI.
Conclusion
In conclusion, patients with STEMI and renal insuffi-
ciency had significantly less chance of receiving optimal
medical care throughout the entire process of MI man-
agement. Despite recent advances in emergency systems
and evidence-based therapy, these advances have been
applied less frequently in patients with renal insuffi-
ciency than in patients with normal renal function.
Therefore, patients with renal insufficiency require an
aggressive approach to diagnosis, intervention, and med-
ical treatment for improved clinical outcomes.
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Appendix 2
Korea Acute Myocardial infarction Registry (KAMIR)
participation centers
Seoul St.Mary's Hospital, Kangdong Sacred Hospital,
Konyang University Hospital, Kyungpook National
University Hospital, Gyeongsang National University
Hospital, Kyunghee Dongsuh University Hospital, Kyun-
ghee University Medical Center, Korea University Guro
Hospital, Kwangju Christian Hospital, National Health
Insurance Corporation Ilsan Hospital, Dankook University
Hospital, Daegu Catholic University Medical Center,
Daejeon Sun Hospital, Daejeon St.Mary's Hospital,
Dongguk University Gyeongju Hospital, Dongsan Medical
Center, Dong-A University Medical Center, Mokpo
Hankuk Hospital, Kwangju Veterans Hospital, Busan
National University Hospital, Busan Marynoll Medical
Center, Busan Paik Hospital, Busan Hanseo Hospital,
Seoul National University Bundang Hospital, Samsung
Medical Center, Inje University Sanggye Paik Hospital,
Seoul National University Hospital, Asan Medical Center,
St. Paul's Hospital, St. Carollo Hospital, Soon Chun
Hyang University Bucheon Hospital, Soon Chun Hyang
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ance Hospital, Ajou University Hospital, Yeouido St.
Mary's Hospital, Yeungnam University Medical Center,
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Wonju University Hospital, Eulji Medical Center,
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University Gil Hospital, Inha University Hospital, Chonnam
National University Hospital, Chonbuk National University
Hospital, Presbyterian Medical Center, Jeju National
University Hospital, Chosun University Hospital, Chung
Ang University Hospital, Chungnam National University
Hospital, Chungbuk National University Hospital, Pohang
Seomyung Christianity Hospital, Hallym University
Medical Center.
Competing interests
The authors declared that they have no competing interest.
Authors’ contributions
JSC and SWK designed research, performed, and wrote the paper. CSK, EHB
and SKM interpreted the data. MHJ, YJK, MCC and CJK were investigators of
Korea Acute Myocardial infarction Registry. All authors read and approved
the final manuscript.
Acknowledgements
This research was supported by Basic Science Research Program through the
National Research Foundation of Korea (NRF) funded by the Ministry of
Education, Science and Technology (2011–0009743), and by the Korea
Science and Engineering Foundation through the Medical Research Center
for Gene Regulation grant (2012–0009448) at Chonnam National University.Author details
1Department of Internal Medicine, Chonnam National University Medical
School, 42 Jebongro, Gwangju 501-757, South Korea. 2Cardiovascular
Research Institute of Chonnam National University, Gwangju, South Korea.
3Department of Internal Medicine, Yeungnam University, Daegu, South
Korea. 4Department of Internal Medicine, Chungbuk National University,
Cheongju, South Korea. 5Department of Internal Medicine, Kyunghee
University, Seoul, South Korea.
Received: 4 March 2012 Accepted: 22 August 2012
Published: 11 September 2012
References
1. VI. Causes of death in ESRD. Am J Kidney Dis 1999, 34(2 Suppl 1):S87–S94.
2. Wolfe RA, Port FK, Webb RL, Bloembergen WE, Hirth R, Young EW, Ojo AO,
Strawderman RL, Parekh R, Stack A, et al: Introduction to the excerpts from
the United States Renal Data System 1999 Annual Data Report. Am J
Kidney Dis 1999, 34(2 Suppl 1):S1–S3.
3. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL,
White HD, Nordlander R, Maggioni A, Dickstein K, et al: Relation between
renal dysfunction and cardiovascular outcomes after myocardial
infarction. N Engl J Med 2004, 351(13):1285–1295.
4. Bae EH LS, Cho KH, Choi JS, Kim CS, Park JW, Ma SK, Jeong MH, Kim SW:
Glomerular filtration rate and cardiovascular outcomes after acute
myocardial infarction: Results from Korea Acute Myocardial infarction
Registry. American J Kidney Dis 2012, 59(6):795–802.
5. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS: Cardiovascular
disease risk factors in chronic kidney disease: overall burden and rates
of treatment and control. Arch Intern Med 2006, 166(17):1884–1891.
6. Ross R: Atherosclerosis–an inflammatory disease. N Engl J Med 1999,
340(2):115–126.
7. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD: Prognostic
assessment of estimated glomerular filtration rate by the new Chronic
Kidney Disease Epidemiology Collaboration equation in comparison with
the Modification of Diet in Renal Disease Study equation. Am Heart J
2011, 162(3):548–554.
8. Choi JS KC, Park JW, Bae EH, Ma SK, Jeong MH, Kim SW: Renal Dysfunction
as a Risk Factor for Painless Myocardial Infarction: Results from Korea
Acute Myocardial Infarction Registry. Clin Res Cardiol. Epub ahead of print.
9. Canto JG, Shlipak MG, Rogers WJ, Malmgren JA, Frederick PD, Lambrew CT,
Ornato JP, Barron HV, Kiefe CI: Prevalence, clinical characteristics, and
mortality among patients with myocardial infarction presenting without
chest pain. JAMA 2000, 283(24):3223–3229.
10. Ross AM, Coyne KS, Moreyra E, Reiner JS, Greenhouse SW, Walker PL,
Simoons ML, Draoui YC, Califf RM, Topol EJ, et al: Extended mortality
benefit of early postinfarction reperfusion, GUSTO-I Angiographic
Investigators. Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries Trial. Circulation 1998,
97(16):1549–1556.
11. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A,
Simoons ML, Morris D, Betriu A, Califf RM: Link between the angiographic
substudy and mortality outcomes in a large randomized trial of
myocardial reperfusion. Importance of early and complete infarct artery
reperfusion. GUSTO-I Investigators. Circulation 1995, 91(7):1923–1928.
12. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM,
Granger CB, Ohman EM, Holmes DR Jr: Prognostic implications of
abnormalities in renal function in patients with acute coronary
syndromes. Circulation 2002, 106(8):974–980.
13. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Pinero G, Avezum A, Gulba D,
Esteban J, Gore JM, Johnson J, et al: Creatinine clearance and adverse
hospital outcomes in patients with acute coronary syndromes: findings
from the global registry of acute coronary events (GRACE). Heart 2003,
89(9):1003–1008.
14. Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing the cardiac
risk profile in chronic hemodialysis patients: a hypothesis on the role of
oxidant stress and other non-traditional cardiac risk factors. J Am Soc
Nephrol 1997, 8(3):475–486.
15. Cauza E, Kletzmaier J, Bodlaj G, Dunky A, Herrmann W, Kostner K:
Relationship of non-LDL-bound apo(a), urinary apo(a) fragments and
plasma Lp(a) in patients with impaired renal function. Nephrol Dial
Transplant 2003, 18(8):1568–1572.
Choi et al. BMC Nephrology 2012, 13:110 Page 9 of 9
http://www.biomedcentral.com/1471-2369/13/11016. Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R: Circulating
thrombomodulin levels are related to latent progression of
atherosclerosis in hypertensive patients. Hypertens Res 2003,
26(6):479–483.
17. Fleck C, Schweitzer F, Karge E, Busch M, Stein G: Serum concentrations of
asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients
with chronic kidney diseases. Clin Chim Acta 2003, 336(1–2):1–12.
18. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL,
Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction
and renal dysfunction: a high-risk combination. Ann Intern Med 2002,
137(7):563–570.
19. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP,
Saucedo JF, Kontos MC, Wiviott SD: Use of evidence-based therapies in
short-term outcomes of ST-segment elevation myocardial infarction and
non-ST-segment elevation myocardial infarction in patients with chronic
kidney disease: a report from the National Cardiovascular Data Acute
Coronary Treatment and Intervention Outcomes Network registry.
Circulation 2010, 121(3):357–365.
20. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M: Are we
inhibited? Renal insufficiency should not preclude the use of ACE
inhibitors for patients with myocardial infarction and depressed left
ventricular function. Arch Intern Med 2000, 160(17):2645–2650.
21. Shlipak MG, Browner WS, Noguchi H, Massie B, Frances CD, McClellan M:
Comparison of the effects of angiotensin converting-enzyme inhibitors
and beta blockers on survival in elderly patients with reduced left
ventricular function after myocardial infarction. Am J Med 2001,
110(6):425–433.
22. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-
converting enzyme inhibitor therapy in patients with end-stage renal
disease and an acute myocardial infarction. J Am Coll Cardiol 2003,
42(2):201–208.
23. McGovern PG, Folsom AR, Sprafka JM, Burke GL, Doliszny KM, Demirovic J,
Naylor JD, Blackburn H: Trends in survival of hospitalized myocardial
infarction patients between 1970 and 1985. The Minnesota Heart
Survey. Circulation 1992, 85(1):172–179.
24. Kilburn H Jr, Schoen L, Wang T: Acute Myocardial Infarction in New York
State: 1996–2008. J Community Health 2011, 37(2):473–479.
25. Lee SH, Kim YJ, Kim W, Park JS, Shin DG, Hur SH, Kim CJ, Cho MC, Chae SC,
Jeong MH, et al: Clinical outcomes and therapeutic strategy in patients
with acute myocardial infarction according to renal function: data
from the Korean Acute Myocardial Infarction Registry. Circ J 2008,
72(9):1410–1418.
doi:10.1186/1471-2369-13-110
Cite this article as: Choi et al.: Suboptimal medical care of patients with
ST-Elevation Myocardial Infarction and Renal Insufficiency: results from
the Korea acute Myocardial Infarction Registry. BMC Nephrology 2012
13:110.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
